This was demonstrated by (1) an inhibition of tumor growth, (2) smaller tumor volumes as assessed by caliper and CT measurements, (3) a lower 18F-FDG accumulation, (4) a smaller Ki67 proliferation index and (5) a lower Akt phosphorylation for mice receiving the NAC-trastuzumab combination. Here, AKT1 is linked to neoplasm.